MeiraGTx Holdings plc
Close on Oct 19, 2026
- Market cap
- $886.46M
- P/E (TTM)
- 13.3
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | Before market open | – | $1.71 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | Before market open | $300.00K | $-0.57 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | $400.00K | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | Before market open | $3.70M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | Before market open | $1.90M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 13, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 14, 2024 | Before market open | – | – | – |
Press releases
Announcements MeiraGTx filed with the SEC
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
Results of operations · EX-99.1 to Form 8-K
MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)
Material agreement · Agreement terminated · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
MeiraGTx Reports First Quarter 2026 Financial and Operational Results
Results of operations · EX-99.1 to Form 8-K
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
Material agreement · Agreement terminated · Acquisition or disposition completed · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential.
Material agreement · Agreement terminated · Acquisition or disposition completed · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the
Material agreement · Results of operations · New financial obligation · EX-99.1 to Form 8-K
MeiraGTx Reports Third Quarter 2025 Financial and Operational Results
Results of operations · EX-99.1 to Form 8-K
MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
MeiraGTx Reports Second Quarter 2025 Financial and Operational Results
Results of operations · EX-99.1 to Form 8-K
MeiraGTx Reports First Quarter 2025 Financial and Operational Results
Results of operations · EX-99.1 to Form 8-K
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease
Regulation FD disclosure · EX-99.1 to Form 8-K
MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3
Material agreement · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates
Material agreement · Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation
Other events · EX-99.1 to Form 8-K
MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates
Results of operations · EX-99.1 to Form 8-K
MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results
Results of operations · EX-99.1 to Form 8-K
MeiraGTx Reports First Quarter 2024 Financial and Operational Results
Results of operations · EX-99.1 to Form 8-K
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
Results of operations · EX-99.1 to Form 8-K
MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals
Other events · EX-99.1 to Form 8-K
MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million
Material agreement · Agreement terminated · Acquisition or disposition completed · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
MeiraGTx Announces Third Quarter 2023 Financial and Operational Results
Results of operations · EX-99.1 to Form 8-K
MeiraGTx Announces $30 Million Strategic Investment from Sanofi;
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
MeiraGTx Reports Second Quarter 2023 Financial and Operational Results
Material agreement · Results of operations · New financial obligation · EX-99.1 to Form 8-K
MeiraGTx Reports First Quarter 2023 Financial and Operational Results
Results of operations · EX-99.1 to Form 8-K
MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results
Results of operations · EX-99.1 to Form 8-K
MeiraGTx Reports Third Quarter 2022 Financial and Operational Results and Receives $25 Million Investment from Johnson & Johnson Innovation - JJDC, Inc.
Material agreement · Results of operations · Unregistered share sale · EX-99.1 to Form 8-K
MeiraGTx Reports Second Quarter 2022 Financial and Operational Results
Results of operations · EX-99.1 to Form 8-K
MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
MeiraGTx Reports First Quarter 2022 Financial and Operational Results
Results of operations · EX-99.1 to Form 8-K
MeiraGTx Appoints Debra Yu, MD to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
MeiraGTx Reports Fourth Quarter and Full Year 2021 Financial and Operational Results
Results of operations · EX-99.1 to Form 8-K
MeiraGTx Announces Positive Preliminary Data from the AQUAx Phase 1 Clinical Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
Regulation FD disclosure · EX-99.1 to Form 8-K
Gene Therapy for the Treatment of Radiation-Induced Xerostomia:
Regulation FD disclosure · EX-99.2 to Form 8-K
MeiraGTx Reports Third Quarter 2021 Financial and Operational Results
Results of operations · EX-99.1 to Form 8-K